AVIR

Atea Pharmaceuticals, Inc.

AVIR · CIK 1593899 · Annual (10-K) · Last 5 years

Financial Trends

Revenue
20202024
Net Income−$168M
20202024
Operating CF−$135M
20202024
Free Cash Flow
20202024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Revenue——$0.4B$0.4B$0.0B
Cost of Revenue—————
Gross Profit—————
R&D Expense$0.1B$0.1B$0.1B$0.2B$0.0B
SG&A Expense—————
Operating Income$-0.2B$-0.2B$-0.1B$0.1B$-0.0B
Net Income$-0.2B$-0.1B$-0.1B$0.1B$-0.0B
EPS (Basic)$-2.00$-1.63$-1.39$1.46—
EPS (Diluted)$-2.00$-1.63$-1.39$1.37—

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Total Assets$0.5B$0.6B$0.7B$0.8B$0.9B
Current Assets$0.5B$0.6B$0.7B$0.8B$0.9B
Cash & Equivalents$0.1B$0.1B$0.2B$0.8B$0.9B
Total Liabilities$0.0B$0.0B$0.0B$0.1B$0.3B
Current Liabilities$0.0B$0.0B$0.0B$0.1B$0.3B
Stockholders' Equity$0.4B$0.6B$0.6B$0.7B$0.5B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Operating Cash Flow$-0.1B$-0.1B$-0.1B$-0.1B$0.3B
Investing Cash Flow$0.1B$0.0B$-0.5B$-0.0B$-0.0B
Capital Expenditures—$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$0.0B$0.0B$0.0B$0.5B
← Companies